A Phase 3 interventional study of Rituximab and Cyclophosphamide in Lymphoma, sponsored by Hoffmann-La Roche. Completed at 39 sites in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-08-13.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 253 studies testing rituximab in Lymphoma — 11 open to participants now, 17 under way, 2 of them phase 3. Rituximab · Lymphoma.
Among the 253 studies testing rituximab in Lymphoma, this one is the 28th largest by enrollment of the 237 interventional ones that give a count, is one of 7 that started in 2013, is one of 26 in phase 3, and was the 216th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →11 of the 253 studies testing rituximab in Lymphoma are open now, in 7 countries. Recruiting first, the newest first:
Gottfried von Keudell, MD PhD · Sites in United States
Ages 18+
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Sites in Portugal, Spain
Ages 18+
Second Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Christine Ryan · Sites in United States
Ages 18+
Christian Buske · Sites in Germany, Greece
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
253 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 184 · Phase 3 28
First in 1995; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 44 across the 237 interventional studies. Of the 212 that completed or were terminated, 102 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 253 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
17 studies in Lymphoma by Hoffmann-La Roche: 1 open now, 3 under way, 1 of them phase 3. Of 14 finished, 8 (57%) have results posted.
Among the 17 studies in Lymphoma by Hoffmann-La Roche, this one is the 5th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 3, and was the 7th registered.
Hoffmann-La Roche’s Lymphoma studies by the year they started, since 2002.
3 of the studies testing rituximab in Lymphoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06573645Phase 3Xia YiA Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | 2027-01-12 |
| NCT05495464M.D. Anderson Cancer CenterA Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | 2027-03-31 |
| NCT06557330Fox Chase Cancer CenterMRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma | 2027-09-29 |
Add all 3 to your calendar (.ics) → With an account.
Among the 253 studies testing rituximab in Lymphoma, from their registry updates:
Among Hoffmann-La Roche’s 17 in Lymphoma:
This tab as a report to print or save as PDF → With an account.
This single arm, multicenter study will evaluate the safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab in previously untreated participants with cluster of differentiation 20 positive (CD20+) DLBCL or FL. In addition to standard chemotherapy, participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.
Drug: Rituximab · Drug: Cyclophosphamide · Drug: Vincristine · Drug: Doxorubicin · Drug: Prednisone · Drug: Bendamustine
Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
Also known as: MabThera, Rituxan
Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
Percentage of Participants With Administration-Associated Reactions (AAR)
AARs were defined as all adverse events (AEs) occurring within 24 hours of rituximab administration and which were considered related to study drug. AARs included infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. Grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
Time frame: Baseline up to 54 months
Percentage of Participants With At Least One Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the CTCAE, version 4.0.
Time frame: Baseline up to 54 months
Percentage of Participants With At Least One Grade ≥ 3 Infusion/ Injection Related Reactions (IIRRs)
Grading of IIRRs was completed according to the CTCAE, version 4.0.
Time frame: Baseline up to 54 months
Percentage of Participants With At Least One Treatment-Emergent Serious Adverse Events
SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.
Time frame: Baseline up to 54 months
Percentage of Participants With Event-Free Survival (EFS) According to IWG Response Criteria
EFS was defined as the time from first dose of rituximab to first occurrence of progression or relapse, according to the International Working Group (IWG) response criteria or other country standards, or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurred first.
Time frame: Day 1 up to first occurrence of progression or relapse, or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurs first (up to maximum 54 months)
Percentage of Participants With Progression-Free Survival (PFS) According to IWG Response Criteria
PFS was defined as the time from first dose of rituximab to the first occurrence of disease progression or relapse, according to the International Working Group (IWG) response criteria or other country standards, or death from any cause, whichever occurred first.
Time frame: Day 1 up to first occurrence of progression or relapse, or death, whichever occurs first (up to maximum 54 months)
Percentage of Participants With Overall Survival (OS)
OS was defined as the time from first dose of rituximab to death from any cause.
Time frame: Day 1 until death (up to maximum 54 months)
Percentage of Participants With Disease-Free Survival (DFS) According to IWG Response Criteria
DFS assessed in participants achieving complete response (CR) including complete response unconfirmed (Cru) and was defined as the period from 4 to 8 weeks after end of Induction period up to relapse or death from any cause, whichever occured first.
Time frame: From 4 to 8 weeks after end of Induction period up to relapse or death from any cause, whichever occurs first (up to maximum 54 months) (end of Induction period = up to 8 months)
Percentage of Participants With Complete Response (CR) According to IWG Response Criteria
Complete response required: 1) the complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities, 2) all lymph nodes and nodal masses had regressed to normal size, 3) the spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and not be palpable on physical examination and 4) if the bone marrow was involved by lymphoma before treatment, the infiltrate was cleared on repeat bone marrow aspirate and biopsy of the same site. CR/unconfirmed (CRu) included those patients who fulfilled criteria 1 and 3 above as well as 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that regressed by more than 75% in the SPD and 2) indeterminate bone marrow. Response was assessed according to the IWG response criteria.
Time frame: At 4 to 8 weeks after end of Induction period (end of Induction period = up to 8 months)
FL: Plasma Trough Concentrations of Rituximab
FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Pharmacokinetic (PK) data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.
Time frame: Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1
FL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab
FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. PK data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.
Time frame: Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1
FL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)
FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. PK data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.
Time frame: Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1
DLBCL: Plasma Concentrations of Rituximab
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
DLBCL: Plasma Trough Concentrations of Rituximab
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 pre-dose on Day 1
DLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of Rituximab
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
DLBCL: Maximum Plasma Concentration (Cmax) of Rituximab
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
DLBCL: Apparent Total Clearance (CL/F) of Rituximab
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
DLBCL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
DLBCL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
DLBCL: Plasma Concentrations During Different Scheduling of Rituximab SC R-CHOP-14 or R-CHOP-21
Plasma concentrations of rituximab in participants with DLBCL by chemotherapy regimen cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 14 days (R-CHOP-14) or cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 21 days (R-CHOP-21) in the PK) population.DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
Rituximab Administration Satisfaction Questionnaire (RASQ) Convenience and Satisfaction Domain Scores
Patient-assessed satisfaction was evaluated using RASQ. Participants were asked questions regarding convenience and satisfaction for rituximab SC. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants. DLBCL participants could be enrolled at cycle 2, cycle 3, or cycle 4. FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must be able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Each Cycle is 21 days for DLBCL. Each Cycle 21 days during the Induction phase and 2 months during Maintenance phase for FL.
Time frame: DLBCL: Cycle (C) 2, C3, C4, C5, C6, End of C8; FL: Induction: C3, C4, C5, C6, C8, Maintenance: C2, C3, C4, C5, C6, C7, C8, C10, C12, End of treatment (4-8 weeks after last dose)
The study was conducted at 37 investigational centers in Italy.
| Milestone | Subcutaneous (SC) Rituximab |
|---|---|
| Started | 158 |
| Completed | 113 |
| Not completed | 45 |
| Withdrew: Death | 18 |
| Withdrew: Progression of disease | 14 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Other | 4 |
| Withdrew: Consent withdrawal | 3 |
AARs were defined as all adverse events (AEs) occurring within 24 hours of rituximab administration and which were considered related to study drug. AARs included infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. Grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
| Percentage of Participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous (SC) Rituximab |
|---|---|---|---|
| At least One AAR | 4.2 | 8.1 | 6.3 |
| At Least One AAR Grade ≥3 | 0 | 0 | 0 |
| Cutaneous and Soft Tissue AARs (Localized) | 1.4 | 8.1 | 5.1 |
| Cutaneous and Soft Tissue AARs (Non-Localized) | 2.8 | 0 | 1.3 |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the CTCAE, version 4.0.
| Percentage of Participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous (SC) Rituximab |
|---|---|---|---|
| Percentage of Participants With At Least One Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs) | 51.4 | 43.0 | 46.8 |
Grading of IIRRs was completed according to the CTCAE, version 4.0.
| Percentage of Participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous (SC) Rituximab |
|---|---|---|---|
| Percentage of Participants With At Least One Grade ≥ 3 Infusion/ Injection Related Reactions (IIRRs) | 0 | 0 | 0 |
SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.
| Percentage of Participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous (SC) Rituximab |
|---|---|---|---|
| Percentage of Participants With At Least One Treatment-Emergent Serious Adverse Events | 36.1 | 26.7 | 31.0 |
EFS was defined as the time from first dose of rituximab to first occurrence of progression or relapse, according to the International Working Group (IWG) response criteria or other country standards, or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurred first.
| Percentage of Participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous (SC) Rituximab |
|---|---|---|---|
| Percentage of Participants With Event-Free Survival (EFS) According to IWG Response Criteria | 29.2 | 22.1 | 25.3 |
PFS was defined as the time from first dose of rituximab to the first occurrence of disease progression or relapse, according to the International Working Group (IWG) response criteria or other country standards, or death from any cause, whichever occurred first.
| Percentage of Participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous (SC) Rituximab |
|---|---|---|---|
| Percentage of Participants With Progression-Free Survival (PFS) According to IWG Response Criteria | 29.2 | 22.1 | 25.3 |
OS was defined as the time from first dose of rituximab to death from any cause.
| Percentage of Participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous (SC) Rituximab |
|---|---|---|---|
| Percentage of Participants With Overall Survival (OS) | 19.4 | 4.7 | 11.4 |
DFS assessed in participants achieving complete response (CR) including complete response unconfirmed (Cru) and was defined as the period from 4 to 8 weeks after end of Induction period up to relapse or death from any cause, whichever occured first.
| Percentage of Participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous (SC) Rituximab |
|---|---|---|---|
| Percentage of Participants With Disease-Free Survival (DFS) According to IWG Response Criteria | 21.7 | 25.6 | 23.5 |
Complete response required: 1) the complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities, 2) all lymph nodes and nodal masses had regressed to normal size, 3) the spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and not be palpable on physical examination and 4) if the bone marrow was involved by lymphoma before treatment, the infiltrate was cleared on repeat bone marrow aspirate and biopsy of the same site. CR/unconfirmed (CRu) included those patients who fulfilled criteria 1 and 3 above as well as 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that regressed by more than 75% in the SPD and 2) indeterminate bone marrow. Response was assessed according to the IWG response criteria.
| Percentage of Participants | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Subcutaneous (SC) Rituximab |
|---|---|---|---|
| Percentage of Participants With Complete Response (CR) According to IWG Response Criteria | 65.2 (52.4 to 76.5) | 67.9 (53.7 to 80.1) | 66.4 (57.2 to 74.8) |
FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Pharmacokinetic (PK) data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.
| micrograms per millilitre (ug/mL) | Follicular Lymphoma (FL) |
|---|---|
| Cycle 2 Predose | 55.49 ± 64.275 |
| Cycle 3 Predose | 119.50 ± 139.606 |
| Cycle 4 Predose | 157.25 ± 132.583 |
| Cycle 5 Predose | 7.60 ± NA |
| Baseline | 90.88 ± 107.089 |
| Cycle 8 Predose | 201.56 ± 372.609 |
FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. PK data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.
| micrograms per millilitre (ug/mL) | Follicular Lymphoma (FL) |
|---|---|
| FL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab | 61.01 (42.49 to 87.61) |
FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. PK data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.
| micrograms per millilitre (ug/mL) | Follicular Lymphoma (FL) |
|---|---|
| Cycle 2 Predose | 48.86 ± 57.640 |
| Cycle 3 Predose | 156.33 ± 193.753 |
| Cycle 4 Predose | 200.33 ± 123.411 |
| Cycle 5 Predose | 7.60 ± NA |
| Baseline | 97.90 ± 118.897 |
| Cycle 8 Predose | 284.08 ± 504.113 |
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
| micrograms per millilitre (ug/mL) | Diffuse Large B-Cell Lymphoma (DLBCL) |
|---|---|
| Cycle 2 Predose | 42.53 ± 49.637 |
| Cycle 3 Predose | 88.92 ± 92.790 |
| Cycle 4 Predose | 110.50 ± 101.116 |
| Cycle 5 Predose | 100.20 ± 44.483 |
| Baseline | 92.92 ± 114.466 |
| Cycle 7 Predose | 141.44 ± 122.314 |
| Cycle 7 Day 7 | 348.81 ± 490.785 |
| Cycle 7 Day 14 | 226.40 ± 136.729 |
| Cycle 8 Predose | 117.61 ± 89.394 |
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
| micrograms per millilitre (ug/mL) | Diffuse Large B-Cell Lymphoma (DLBCL) |
|---|---|
| Cycle 2 Predose | 42.53 ± 49.637 |
| Cycle 3 Predose | 88.92 ± 92.790 |
| Cycle 4 Predose | 110.50 ± 101.116 |
| Cycle 5 Predose | 100.20 ± 44.483 |
| Baseline | 92.92 ± 114.466 |
| Cycle 7 Predose | 141.44 ± 122.314 |
| Cycle 8 Predose | 117.61 ± 89.394 |
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
| mcg*hr/mL | Diffuse Large B-Cell Lymphoma (DLBCL) |
|---|---|
| DLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of Rituximab | NA ± NA |
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
| micrograms per millilitre (ug/mL) | Diffuse Large B-Cell Lymphoma (DLBCL) |
|---|---|
| DLBCL: Maximum Plasma Concentration (Cmax) of Rituximab | NA ± NA |
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
| liter per hour (L/h) | Diffuse Large B-Cell Lymphoma (DLBCL) |
|---|---|
| DLBCL: Apparent Total Clearance (CL/F) of Rituximab | NA ± NA |
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
| micrograms per millilitre (ug/mL) | Diffuse Large B-Cell Lymphoma (DLBCL) |
|---|---|
| Cycle 2 Predose | 53.97 ± 56.169 |
| Cycle 3 Predose | 101.79 ± 101.223 |
| Cycle 4 Predose | 110.50 ± 101.116 |
| Cycle 5 Predose | 121.67 ± 45.092 |
| Baseline | 109.40 ± 125.603 |
| Cycle 7 Predose | 157.93 ± 131.178 |
| Cycle 8 Predose | 132.57 ± 95.447 |
DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
| micrograms per millilitre (ug/mL) | Diffuse Large B-Cell Lymphoma (DLBCL) |
|---|---|
| DLBCL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab | 70.50 (57.60 to 86.28) |
Plasma concentrations of rituximab in participants with DLBCL by chemotherapy regimen cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 14 days (R-CHOP-14) or cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 21 days (R-CHOP-21) in the PK) population.DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.
| micrograms per millilitre (ug/mL) | Diffuse Large B-Cell Lymphoma (DLBCL) R-CHOP-14 | Diffuse Large B-Cell Lymphoma (DLBCL) R-CHOP-21 |
|---|---|---|
| Cycle 2 Predose | 170.00 ± NA | 28.37 ± 22.695 |
| Cycle 3 Predose | — | 88.92 ± 92.790 |
| Cycle 4 Predose | — | 110.50 ± 101.116 |
| Cycle 5 Predose | 125.00 ± NA | 94.00 ± 48.806 |
| Baseline | 214.25 ± 233.493 | 74.25 ± 77.064 |
| Cycle 7 Predose | 93.50 ± 79.903 | 150.13 ± 126.221 |
| Cycle 7 Day 7 | 71.55 ± 26.092 | 398.76 ± 517.974 |
| Cycle 7 Day 14 | 42.00 ± NA | 272.50 ± 103.722 |
| Cycle 8 Predose | 78.50 ± 14.849 | 123.76 ± 92.606 |
Patient-assessed satisfaction was evaluated using RASQ. Participants were asked questions regarding convenience and satisfaction for rituximab SC. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants. DLBCL participants could be enrolled at cycle 2, cycle 3, or cycle 4. FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must be able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Each Cycle is 21 days for DLBCL. Each Cycle 21 days during the Induction phase and 2 months during Maintenance phase for FL.
| Units on a Scale | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) |
|---|---|---|
| Convenience domain Cycle 3 Induction | — | 81.8 ± 8.66 |
| Convenience domain Cycle 4 Induction | — | 76.5 ± 6.26 |
| Convenience domain Cycle 5 Induction | — | 79.6 ± 10.30 |
| Convenience domain Cycle 6 Induction | — | 95.8 ± 5.89 |
| Convenience domain Cycle 8 Induction | — | 83.1 ± 9.18 |
| Convenience domain Cycle 2 Treatment | 75.0 ± NA | — |
| Convenience domain Cycle 3 Treatment | 81.9 ± 10.28 | — |
| Convenience domain Cycle 4 Treatment | 82.1 ± 12.17 | — |
| Convenience domain Cycle 5 Treatment | 83.3 ± 9.96 | — |
| Convenience domain Cycle 6 Treatment | 80.8 ± 9.85 | — |
| Convenience domain Cycle 8 Treatment | 83.8 ± 11.60 | — |
| Convenience domain Cycle 2 Maintenance | — | 83.6 ± 8.71 |
| Convenience domain Cycle 3 Maintenance | — | 87.5 ± 19.54 |
| Convenience domain Cycle 4 Maintenance | — | 100.0 ± 0.00 |
| Convenience domain Cycle 5 Maintenance | — | 80.2 ± 12.55 |
| Convenience domain Cycle 6 Maintenance | — | 83.3 ± 16.67 |
| Convenience domain Cycle 7 Maintenance | — | 82.7 ± 12.59 |
| Convenience domain Cycle 8 Maintenance | — | 93.8 ± 12.50 |
| Convenience domain Cycle 10 Maintenance | — | 91.7 ± NA |
| Convenience domain Cycle 12 Maintenance | — | 86.3 ± 12.69 |
| Convenience domain End of Treatment | — | 75.0 ± 16.67 |
| Satisfaction domain Cycle 3 Induction | — | 89.4 ± 10.23 |
| Satisfaction domain Cycle 4 Induction | — | 84.1 ± 13.80 |
| Satisfaction domain Cycle 5 Induction | — | 91.7 ± 8.84 |
| Satisfaction domain Cycle 6 Induction | — | 93.8 ± 8.84 |
| Satisfaction domain Cycle 8 Induction | — | 91.3 ± 9.47 |
| Satisfaction domain Cycle 2 Treatment | 87.5 ± NA | — |
| Satisfaction domain Cycle 3 Treatment | 83.3 ± 11.53 | — |
| Satisfaction domain Cycle 4 Treatment | 85.6 ± 13.62 | — |
| Satisfaction domain Cycle 5 Treatment | 83.3 ± 8.84 | — |
| Satisfaction domain Cycle 6 Treatment | 84.6 ± 14.57 | — |
| Satisfaction domain Cycle 8 Treatment | 91.2 ± 12.76 | — |
| Satisfaction domain Cycle 2 Maintenance | — | 92.0 ± 9.28 |
| Satisfaction domain Cycle 3 Maintenance | — | 79.2 ± 20.41 |
| Satisfaction domain Cycle 4 Maintenance | — | 100.0 ± NA |
| Satisfaction domain Cycle 5 Maintenance | — | 79.7 ± 16.28 |
| Satisfaction domain Cycle 6 Maintenance | — | 87.5 ± 17.68 |
| Satisfaction domain Cycle 7 Maintenance | — | 94.2 ± 9.00 |
| Satisfaction domain Cycle 8 Maintenance | — | 93.8 ± 7.22 |
| Satisfaction domain Cycle 10 Maintenance | — | 50.0 ± NA |
| Satisfaction domain Cycle 12 Maintenance | — | 91.0 ± 13.21 |
| Satisfaction domain End of Treatment | — | 75.0 ± 21.65 |
Collected over Baseline up to 54 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma (DLBCL) | 14/72 (19.4%) | 26/72 (36.1%) | 50/72 (69.4%) |
| Follicular Lymphoma (FL) | 4/86 (4.7%) | 23/86 (26.7%) | 56/86 (65.1%) |
| Event | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 15/72 | 13/86 |
| Neutrophil Count DecreasedInvestigations | 5/72 | 1/86 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 4/72 | 2/86 |
| PneumoniaInfections and infestations | 2/72 | 0/86 |
| White Blood Cell Count DecreasedInvestigations | 2/72 | 0/86 |
| LymphopeniaBlood and lymphatic system disorders | 0/72 | 2/86 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/72 | 2/86 |
| Cholecystitis AcuteHepatobiliary disorders | 0/72 | 2/86 |
| CholelithiasisHepatobiliary disorders | 0/72 | 2/86 |
| LeukopeniaBlood and lymphatic system disorders | 1/72 | 1/86 |
| Event | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 21/72 | 20/86 |
| AstheniaGeneral disorders | 14/72 | 3/86 |
| PyrexiaGeneral disorders | 11/72 | 15/86 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/72 | 15/86 |
| AnaemiaBlood and lymphatic system disorders | 11/72 | 6/86 |
| Neutrophil Count DecreasedInvestigations | 9/72 | 1/86 |
| ParaesthesiaNervous system disorders | 9/72 | 7/86 |
| Influenza Like IllnessGeneral disorders | 2/72 | 9/86 |
| DiarrhoeaGastrointestinal disorders | 7/72 | 7/86 |
| LeukopeniaBlood and lymphatic system disorders | 2/72 | 7/86 |
ITT population included all enrolled participants. All analyses described have been performed by type of lymphoma (DLBCL/ FL) and overall. Total overall participants enrolled in the study was 159, however for the subject disposition and baseline characteristics the enrolled was 158 as one participant discontinued the study prior to treatment.
| Age, Continuous(years) | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Total |
|---|---|---|---|
| Intent-to-Treat Population | 59.7 ± 12.70 | 57.8 ± 9.92 | 58.7 ± 11.28 |
| Sex: Female, Male(Participants) | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Total |
|---|---|---|---|
| Female | 28 | 44 | 72 |
| Male | 44 | 42 | 86 |
| Ethnicity (NIH/OMB)(Participants) | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 9 |
| Not Hispanic or Latino | 59 | 72 | 131 |
| Unknown or Not Reported | 9 | 9 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Jul 2013 to primary completion in May 2019, 69 months.
Results were first posted in Aug 2020, 1 year 2 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 69. This study's 69 months is above that.
Counting every sponsor, half of 62 studies reached it within 67 months; a quarter within 52 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab